Formulation And Evaluation Of Controlled Release Aspirin Tablets
Aspirin is known to be effective in primary and secondary prevention of myocardial infarction. For this purpose aspirin release should be such that It prevents platelet thromboxane (TXA2) generation without Interfering with vascular prostacyclin (PGI2) production. Hence controlled release tablets were prepared to meet the requirements. Both In vitro dissolution and In vivo urinary excretion studies were done to ensure the effectiveness of the formulations. The study proves the usefulness of Carbopol resins for formulating aspirin tablets for minimum risk and maximum therapeutic benefit to the patient.